These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 28212926)

  • 21. Treating relapsing multiple sclerosis with dimethyl fumarate.
    McCarty DJ
    Nurse Pract; 2017 Jul; 42(7):8-10. PubMed ID: 28622251
    [No Abstract]   [Full Text] [Related]  

  • 22. Dimethyl Fumarate Treatment Mediates an Anti-Inflammatory Shift in B Cell Subsets of Patients with Multiple Sclerosis.
    Li R; Rezk A; Ghadiri M; Luessi F; Zipp F; Li H; Giacomini PS; Antel J; Bar-Or A
    J Immunol; 2017 Jan; 198(2):691-698. PubMed ID: 27974457
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An unusual infection in MS patient treated with dimethyl fumarate: A case report of omphalitis.
    Lorefice L; Fenu G; Cabras F; Frau J; Coghe GC; Loi L; Marrosu MG; Cocco E
    Mult Scler Relat Disord; 2016 May; 7():65-7. PubMed ID: 27237760
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dimethyl fumarate for relapsing-remitting multiple sclerosis.
    Drug Ther Bull; 2014 Sep; 52(9):105-8. PubMed ID: 25213591
    [TBL] [Abstract][Full Text] [Related]  

  • 25. COVID-19 in multiple sclerosis patients treated with dimethyl fumarate.
    Capone F; Ferraro E; Motolese F; Di Lazzaro V
    J Neurol; 2021 Sep; 268(9):3132-3134. PubMed ID: 33611610
    [No Abstract]   [Full Text] [Related]  

  • 26. The "poison chair" treatment for multiple sclerosis.
    Ropper AH
    N Engl J Med; 2012 Sep; 367(12):1149-50. PubMed ID: 22992079
    [No Abstract]   [Full Text] [Related]  

  • 27. Dimethyl fumarate in relapsing-remitting multiple sclerosis: rationale, mechanisms of action, pharmacokinetics, efficacy and safety.
    Dubey D; Kieseier BC; Hartung HP; Hemmer B; Warnke C; Menge T; Miller-Little WA; Stuve O
    Expert Rev Neurother; 2015 Apr; 15(4):339-46. PubMed ID: 25800129
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment with Dimethyl Fumarate Enhances Cholinergic Transmission in Multiple Sclerosis.
    Nicoletti CG; Landi D; Monteleone F; Mataluni G; Albanese M; Lauretti B; Rocchi C; Simonelli I; Boffa L; Buttari F; Mercuri NB; Centonze D; Marfia GA
    CNS Drugs; 2019 Nov; 33(11):1133-1139. PubMed ID: 31650471
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Progressive familial intrahepatic cholestasis type-3 and multiple sclerosis: lessons from comorbidity.
    De Masi R; Orlando S; De Donno A
    Ann Clin Transl Neurol; 2019 Nov; 6(11):2347-2350. PubMed ID: 31568708
    [TBL] [Abstract][Full Text] [Related]  

  • 30. PML during dimethyl fumarate treatment of multiple sclerosis: How does lymphopenia matter?
    Lehmann-Horn K; Penkert H; Grein P; Leppmeier U; Teuber-Hanselmann S; Hemmer B; Berthele A
    Neurology; 2016 Jul; 87(4):440-1. PubMed ID: 27343070
    [No Abstract]   [Full Text] [Related]  

  • 31. Comparative efficacy and discontinuation of dimethyl fumarate and fingolimod in clinical practice at 12-month follow-up.
    Hersh CM; Love TE; Cohn S; Hara-Cleaver C; Bermel RA; Fox RJ; Cohen JA; Ontaneda D
    Mult Scler Relat Disord; 2016 Nov; 10():44-52. PubMed ID: 27919497
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Legionella infection associated with dimethyl fumarate used for treatment of multiple sclerosis.
    Rastas C; Sirignano D; Barner A; Bruno-Murtha LA
    J Neurol; 2019 Nov; 266(11):2867-2868. PubMed ID: 31350640
    [No Abstract]   [Full Text] [Related]  

  • 33. Dimethyl fumarate associated lymphopenia in clinical practice.
    Longbrake EE; Cross AH
    Mult Scler; 2015 May; 21(6):796-7. PubMed ID: 25432948
    [No Abstract]   [Full Text] [Related]  

  • 34. The real-world patient experience of fingolimod and dimethyl fumarate for multiple sclerosis.
    Wicks P; Rasouliyan L; Katic B; Nafees B; Flood E; Sasané R
    BMC Res Notes; 2016 Sep; 9(1):434. PubMed ID: 27604188
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dimethyl Fumarate-Associated Enterocolitis.
    Bajwa NA; Bajwa AA; Ghazala S; Masood U
    Am J Ther; 2024 Jul-Aug 01; 31(4):e448-e450. PubMed ID: 38525954
    [No Abstract]   [Full Text] [Related]  

  • 36. Real-life persistence and tolerability with dimethyl fumarate.
    Sejbaek T; Nybo M; Petersen T; Illes Z
    Mult Scler Relat Disord; 2018 Aug; 24():42-46. PubMed ID: 29906666
    [TBL] [Abstract][Full Text] [Related]  

  • 37. COVID-19 in dimethyl fumarate-treated patients with multiple sclerosis.
    Mantero V; Abate L; Basilico P; Balgera R; Salmaggi A; Nourbakhsh B; Cordano C
    J Neurol; 2021 Jun; 268(6):2023-2025. PubMed ID: 32588182
    [No Abstract]   [Full Text] [Related]  

  • 38. Teaching Neuro
    Tsivgoulis G; Papadimitropoulos GN; Katsanos AH; Zompola C; Safouris A; Kargiotis O; Voumvourakis K
    Neurology; 2017 Oct; 89(15):e188-e189. PubMed ID: 28993534
    [No Abstract]   [Full Text] [Related]  

  • 39. Dimethyl fumarate promotes B cell-mediated anti-inflammatory cytokine profile in B and T cells, and inhibits immune cell migration in patients with MS.
    Najjar E; Staun-Ram E; Volkowich A; Miller A
    J Neuroimmunol; 2020 Jun; 343():577230. PubMed ID: 32247228
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Allergy and dimethyl fumarate treatment in a patient with multiple sclerosis.
    Gelibter S; Orrico M; Moiola L; Dagna L; Filippi M; Yacoub MR
    J Neurol Sci; 2020 Nov; 418():117104. PubMed ID: 32871512
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.